Complementary and alternative medicine in inflammatory bowel diseases: What is the future in the field of herbal medicine?

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 7, 2014, Pages 835-846

  Gilardi, Daniela ^a   Fiorino, Gionata ^a   Genua, Marco ^a   Allocca, Mariangela ^a   Danese, Silvio ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

boswellic acid; complementary and alternative medicine; Crohn's disease; curcumin; herbal medicine; inflammatory bowel disease; pomegranate; ulcerative colitis

Indexed keywords

ACETYLSALICYLIC ACID; BOSWELLIA SERRATA EXTRACT; CLOPIDOGREL; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; NATURAL PRODUCT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POMEGRANATE EXTRACT; SALAZOSULFAPYRIDINE; CURCUMIN;

ALLOPATHY; ALTERNATIVE MEDICINE; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BURN; COLITIS; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CURCUMA LONGA; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; EPIGASTRIC PAIN; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; INFLAMMATORY BOWEL DISEASE; NAUSEA; NONHUMAN; QUALITY OF LIFE; REVIEW; ULCERATIVE COLITIS; ADVERSE EFFECTS; BOSWELLIA; HERBAL MEDICINE; INFLAMMATORY BOWEL DISEASES; LYTHRACEAE; TREATMENT OUTCOME; TRENDS;

BOSWELLIA; COMPLEMENTARY THERAPIES; CURCUMIN; HERBAL MEDICINE; HUMANS; INFLAMMATORY BOWEL DISEASES; PUNICACEAE; TREATMENT OUTCOME;

EID: 84906346637     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.917954     Document Type: Review

References (89)

1. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol 2006;12(30):4807-12
2. Fiocchi C. Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. Am J Physiol 1997;273(4 Pt 1):G769-75
3. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115(1):182-205
4. Shih DQ, Targan SR. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol 2008;14(3):390-400
5. Danese S. Immune and nonimmune components orchestrate the pathogenesis of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2011;300(5): G716-22
6. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012;61(6):918-32
7. Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J Intern Med 2008;263(6):591-6
8. Fiorino G, Correale C, Fries W, et al. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease. Expert Rev Clin Immunol 2010; 6(4):567-72
9. Godkin AJ, De Belder AJ, Villa L, et al. Expression of nitric oxide synthase in ulcerative colitis. Eur J Clin Invest 1996; 26(10):867-72
10. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 2007;52(9):2015-21
11. Mccafferty DM. Peroxynitrite and inflammatory bowel disease. Gut 2000; 46(3):436-9
12. Li R, Alex P, Ye M, et al. An old herbal medicine with a potentially new therapeutic application in inflammatory bowel disease. Int J Clin Exp Med 2011;4(4):309-19
13. Quattropani C, Ausfeld B, Straumann A, et al. Complementary alternative medicine in patients with inflammatory bowel disease: use and attitudes. Scand J Gastroenterol 2003;38(3):277-82
14. Rahimi R, Nikfar S, Abdollahi M. Induction of clinical response and remission of inflammatory bowel disease by use of herbal medicines: a meta-analysis. World J Gastroenterol 2013;19(34):5738-49
15. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000; 118(2 Suppl 1):S68-82
16. Sands BE. New therapies for the treatment of inflammatory bowel disease. Surg Clin North Am 2006;86(4):1045-64
17. Horne R, Parham R, Driscoll R, Robinson A. Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2009;15(6):837-44
18. Lakatos PL. Prevalence, predictors, and clinical consequences of medical adherence in IBD: how to improve it? World J Gastroenterol 2009;15(34):4234-9
19. Rahimi R, Mozaffari S, Abdollahi M. On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies. Dig Dis Sci 2009;54(3):471-80
20. Ke F, Yadav PK, Ju LZ. Herbal medicine in the treatment of ulcerative colitis. Saudi J Gastroenterol 2012;18(1):3-10
21. Langmead L, Rampton DS. Review article: complementary and alternative therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2006;23(3):341-9
22. Ng SC, Lam YT, Tsoi KK, et al. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2013;38(8):854-63
23. Camacho-Barquero L, Villegas I, Sanchez-Calvo JM, et al. Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol 2007;7(3):333-42
24. Deguchi Y, Andoh A, Inatomi O, et al. Curcumin prevents the development of dextran sulfate Sodium (DSS)-induced experimental colitis. Dig Dis Sci 2007; 52(11):2993-8
25. Jian YT, Mai GF, Wang JD, et al. Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol 2005;11(12):1747-52
26. Jian YT, Wang JD, Mai GF, et al. [Modulation of intestinal mucosal inflammatory factors by curcumin in rats with colitis]. Di Yi Jun Yi Da Xue Xue Bao 2004;24(12):1353-8
27. Jiang H, Deng CS, Zhang M, Xia J. Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2. World J Gastroenterol 2006;12(24):3848-53
28. Sugimoto K, Hanai H, Tozawa K, et al. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 2002;123(6): 1912-22
29. Ukil A, Maity S, Karmakar S, et al. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 2003;139(2):209-18
30. Zhang M, Deng C, Zheng J, et al. Curcumin inhibits trinitrobenzene sulphonic acid-induced colitis in rats by activation of peroxisome proliferator-activated receptor gamma. Int Immunopharmacol 2006;6(8): 1233-42
31. Zhang M, Deng CS, Zheng JJ, Xia J. Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis. Acta Pharmacol Sin 2006; 27(8):1071-7
32. Anthoni C, Laukoetter MG, Rijcken E, et al. Mechanisms underlying the antiinflammatory actions of boswellic acid derivatives in experimental colitis. Am J Physiol Gastrointest Liver Physiol 2006; 290(6):G1131-7
33. Gerhardt H, Seifert F, Buvari P, et al. [Therapy of active Crohn disease with Boswellia serrata extract H 15]. Z Gastroenterol 2001;39(1):11-17
34. Gupta I, Parihar A, Malhotra P, et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 2001;67(5):391-5
35. Gupta I, Parihar A, Malhotra P, et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 1997;2(1):37-43
36. Kiela PR, Midura AJ, Kuscuoglu N, et al. Effects of Boswellia serrata in mouse models of chemically induced colitis. Am J Physiol Gastrointest Liver Physiol 2005;288(4): G798-808
37. Krieglstein CF, Anthoni C, Rijcken EJ, et al. Acetyl-11-keto-beta- boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int J Colorectal Dis 2001;16(2):88-95
38. Holtmeier W, Zeuzem S, Preiss J, et al. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: good safety profile but lack of efficacy. Inflamm Bowel Dis 2011;17(2): 573-82
39. Colombo E, Sangiovanni E, Dell'agli M. A review on the anti-inflammatory activity of pomegranate in the gastrointestinal tract. Evid Based Complement Alternat Med 2013;2013:247145
40. Darji VC, Bariya AH, Deshpande SS, Patel DA. Effect of punica granatum fruits in inflammatory bowel disease. J Pharm Res 2010;3(12):3
41. Johanningsmeier SD, Harris GK. Pomegranate as a functional food and nutraceutical source. Annu Rev Food Sci Technol 2011;2:181-201
42. Jurenka JS. Therapeutic applications of pomegranate (Punica granatum L.): a review. Altern Med Rev 2008;13(2): 128-44
43. Lansky EP, Newman RA. Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer. J Ethnopharmacol 2007;109(2): 177-206
44. Viladomiu M, Hontecillas R, Lu P, Bassaganya-Riera J. Preventive and prophylactic mechanisms of action of pomegranate bioactive constituents. Evid Based Complement Alternat Med 2013;2013:789764
45. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4(12): 1502-6
46. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 2008;75(4): 787-809
47. Hanai H, Sugimoto K. Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr Pharm Des 2009;15(18):2087-94
48. Shishodia S, Singh T, Chaturvedi MM. Modulation of transcription factors by curcumin. Adv Exp Med Biol 2007;595: 127-48
49. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001; 21(4B):2895-900
50. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 2005;50(11): 2191-3
51. Rasyid A, Lelo A. The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Aliment Pharmacol Ther 1999;13(2):245-9
52. Rasyid A, Rahman AR, Jaalam K, Lelo A. Effect of different curcumin dosages on human gall bladder. Asia Pac J Clin Nutr 2002;11(4):314-18
53. Srivastava R, Dikshit M, Srimal RC, Dhawan BN. Anti-thrombotic effect of curcumin. Thromb Res 1985;40(3): 413-17
54. Srivastava KC, Bordia A, Verma SK. Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins Leukot Essent Fatty Acids 1995;52(4):223-7
55. Frank MB, Yang Q, Osban J, et al. Frankincense oil derived from Boswellia carteri induces tumor cell specific cytotoxicity. BMC Complement Altern Med 2009;9:6
56. Sterk V, Buchele B, Simmet T. Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteers. Planta Med 2004; 70(12):1155-60
57. Frank A, Unger M. Analysis of frankincense from various Boswellia species with inhibitory activity on human drug metabolising cytochrome P450 enzymes using liquid chromatography mass spectrometry after automated on-line extraction. J Chromatogr A 2006;1112(1-2): 255-62
58. Ricci D, Giamperi L, Bucchini A, Fraternale D. Antioxidant activity of Punica granatum fruits. Fitoterapia 2006;77(4): 310-12
59. Adams LS, Seeram NP, Aggarwal BB, et al. Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J Agric Food Chem 2006;54(3):980-5
60. Gil MI, Tomas-Barberan FA, Hess-Pierce B, et al. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem 2000;48(10):4581-9
61. Zhang LH, Li LL, Li YX, Zhang YH. In vitro antioxidant activities of fruits and leaves of pomegranate. Acta Hort 2008;765:3
62. Kelawala NS, Ananthanarayan L. Antioxidant activity of selected foodstuffs. Int J Food Sci Nutr 2004;55(6):511-16
63. Kaufman M, Wiesman Z. Pomegranate oil analysis with emphasis on MALDI-TOF/MS triacylglycerol fingerprinting. J Agric Food Chem 2007;55(25):10405-13
64. Halvorsen BL, Holte K, Myhrstad MC, et al. A systematic screening of total antioxidants in dietary plants. J Nutr 2002; 132(3):461-71
65. Wolfe KL, Kang X, He X, et al. Cellular antioxidant activity of common fruits. J Agric Food Chem 2008;56(18):8418-26
66. Gonzalez-Sarrias A, Larrosa M, Tomas-Barberan FA, et al. NF-kappaB-dependent anti-inflammatory activity of urolithins, gut microbiota ellagic acid-derived metabolites, in human colonic fibroblasts. Br J Nutr 2010;104(4): 503-12
67. Romier-Crouzet B, Van De Walle J, During A, et al. Inhibition of inflammatory mediators by polyphenolic plant extracts in human intestinal Caco-2 cells. Food Chem Toxicol 2009;47(6):1221-30
68. Bialonska D, Ramnani P, Kasimsetty SG, et al. The influence of pomegranate byproduct and punicalagins on selected groups of human intestinal microbiota. Int J Food Microbiol 2010;140(2-3):175-82
69. Bassaganya-Riera J, Diguardo M, Climent M, et al. Activation of PPARgamma and delta by dietary punicic acid ameliorates intestinal inflammation in mice. Br J Nutr 2011;106(6):878-86
70. Ogawa Y, Kanatsu K, Iino T, et al. Protection against dextran sulfate sodium-induced colitis by microspheres of ellagic acid in rats. Life Sci 2002;71(7): 827-39
71. Singh K, Jaggi AS, Singh N. Exploring the ameliorative potential of Punica granatum in dextran sulfate sodium induced ulcerative colitis in mice. Phytother Res 2009;23(11): 1565-74
72. Umesalma S, Sudhandiran G. Differential inhibitory effects of the polyphenol ellagic acid on inflammatory mediators NF-kappaB, iNOS, COX-2, TNF-alpha, and IL-6 in 1, 2-dimethylhydrazine-induced rat colon carcinogenesis. Basic Clin Pharmacol Toxicol 2010;107(2):650-5
73. Seeram NP, Zhang Y, Mckeever R, et al. Pomegranate juice and extracts provide similar levels of plasma and urinary ellagitannin metabolites in human subjects. J Med Food 2008;11(2):390-4
74. Nagata M, Hidaka M, Sekiya H, et al. Effects of pomegranate juice on human cytochrome P450 2C9 and tolbutamide pharmacokinetics in rats. Drug Metab Dispos 2007;35(2):302-5
75. Hidaka M, Okumura M, Fujita K, et al. Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug Metab Dispos 2005;33(5):644-8
76. Farkas D, Oleson LE, Zhao Y, et al. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. J Clin Pharmacol 2007;47(3):286-94
77. Harputluoglu MM, Demirel U, Yucel N, et al. The effects of Gingko biloba extract on acetic acid-induced colitis in rats. Turk J Gastroenterol 2006;17(3):177-82
78. Mustafa A, El-Medany A, Hagar HH, El-Medany G. Ginkgo biloba attenuates mucosal damage in a rat model of ulcerative colitis. Pharmacol Res 2006;53(4):324-30
79. De Smet PA. Health risks of herbal remedies: an update. Clin Pharmacol Ther 2004;76(1):1-17
80. Ben-Arye E, Goldin E, Wengrower D, et al. Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol 2002;37(4):444-9
81. Langmead L, Feakins RM, Goldthorpe S, et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther 2004;19(7):739-47
82. Krebs S, Omer TN, Omer B. Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease-a controlled clinical trial. Phytomedicine 2010;17(5):305-9
83. Omer B, Krebs S, Omer H, Noor TO. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study. Phytomedicine 2007;14(2-3):87-95
84. Sandborn WJ, Targan SR, Byers VS, et al. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol 2013;108(1):90-8
85. Tang T, Targan SR, Li ZS, et al. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis-a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther 2011;33(2):194-202
86. Vickers KA, Jolly KB, Greenfield SM. Herbal medicine: women's views, knowledge and interaction with doctors: a qualitative study. BMC Complement Altern Med 2006;6:40
87. European Medicinal Agency Herbal medicinal products. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/ general-content-000208. jsp&mid=WC0b01ac05800240cf [Last accessed on 21 March 2014]
88. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53(11):1617-23
89. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354(9179):635-9